Inflammation and surfactant.
An intact and well-functioning pulmonary surfactant system is critical for normal respiration and protection from lung infection. Surfactant is comprised of phospholipids that reduce surface tension and greatly reduce the work of breathing. The other major component consists of surfactant-associated proteins, which optimise the biophysical function of phospholipids and/or play an important role in host defence by acting as collectins. Alteration of surfactant composition and function occurs with various inflammatory disorders that affect the airways or the lung parenchyma including asthma, infant respiratory distress syndrome/bronchopulmonary dysplasia, cystic fibrosis, acute respiratory distress syndrome and interstitial lung disease. Although surfactant replacement therapy is indicated for infant respiratory distress syndrome, there is no well-proven role for exogenous surfactant in the treatment of inflammatory lung disorders at the present time.
Meyer
Keith C
KC
Department of Medicine, K4/930 Clinical Sciences Center, 600 Highland Avenue, Madison, WI 53792-9988, USA. kcm@medicine.wisc.edu
Zimmerman
Jerry J
JJ
D000367:Age Factors; D002648:Child; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007249:Inflammation / Q000150:complications / Q000188:drug therapy*; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000150:complications / Q000188:drug therapy*
D011663:Pulmonary Surfactants